login
Password reminder
Cardiovascular News
Contact the editor Visit Cardiovascular News Twitter feed Visit Cardiovascular News Facebook page
 

Catheter-based ultrasound technology lower resistant hypertension, SOUND ITV study shows


Wednesday, 15 Aug 2012 11:36
Vivek Reddy
Vivek Reddy


On 14 August, Sound Interventions released three-month data from the company’s first-in-human clinical study (SOUND-ITV) to treat resistant hypertension through the use of catheter-based ultrasound.  


In addition to office-based blood pressure measurements, patients in the study underwent 24-hour ambulatory blood pressure monitoring prior to the ultrasonic renal denervation procedure, and subsequently three months after the procedure. The office-based blood pressure measurement results showed an average decrease of -25.6/-12.5 mm Hg. Consistent with these results the 24-hour mean blood pressure decreased by -23.1/-11.9 mm Hg.

Patients were treated at Holmolka Hospital in Prague, Czech Republic. Patients enrolled in the study were selected based on a history of hypertension which could not be controlled with medical therapy. The SOUND-ITV study was designed to evaluate the safety and effectiveness of the company’s volumetric dosimetry-controlled application of unfocused ultrasound (patents pending).


“These results demonstrate the ability of Sound Interventions’ ultrasound technology to significantly lower blood pressure in patients whose blood pressure was unable to be controlled by conventional pharmaceutical therapy,” said Petr Neuzil, chairman, Department of Cardiology of Holmolka Hospital.


Vivek Reddy, Mt Sinai Medical Center in New York City who collaborated with Neuzil and who is an advisor to Sound Interventions, commented: “The use of 24-hour monitoring to assess results of renal denervation procedures is a more accurate measurement of effectiveness than office-based blood pressure. The favorable results seen on the ambulatory blood pressure monitoring fortify our confidence in the efficacy of this technology.”


“These results, demonstrate the efficacy of Sound Interventions ultrasound dosimetry-controlled approach to renal denervation. Prior to initiation of the SOUND-ITV study, the company performed extensive in-vitro and in-vivo testing in order to perfect the ultrasound dosimetry. The pre-clinical testing has demonstrated that the Sound Interventions technology is unique in its ability to ablate the target nerve fibers while sparing the arterial wall,” said David Smith, president and CEO of Sound Interventions. “The success of the acute procedures in the SOUND-ITV study, along with these very strong clinical results validate this research and indicate that we are well on the way to developing the state-of-the-art renal denervation technology.”


Results of the SOUND-ITV study will be presented at the upcoming TCT 2012 Conference (Miami, USA, 22–26 October 2012).




Add New Comment

Related Items


Most popular


Medical devices available in the EU before the USA are at higher risk for emergence of safety issues
Thursday, 30 Jun 2016
A cohort study has found that medical devices approved first in the European Union (EU) are associated with a greater rate of post-marketing safety alerts and recalls compared with devices approved ... Medical devices available in the EU before the USA are at higher risk for emergence of safety issues

Industry-sponsored meals linked to increased rate of prescribing brand-name drugs
Friday, 01 Jul 2016
A study, published in the JAMA: Internal Medicine, indicates that doctors who receive industry-sponsored meals have higher rates of brand-name drug prescriptions than alternative options within the ... Industry-sponsored meals linked to increased rate of prescribing brand-name drugs

CE mark for QT Vascular’s Chocolate Heart drug-coated balloon
Thursday, 07 Jul 2016
QT Vascular has received CE mark clearance for the sale and distribution of its Chocolate Heart drug-coated balloon for dilatation of the stenotic portion of coronary arteries for the purpose of ... CE mark for QT Vascular’s Chocolate Heart drug-coated balloon

Features


TAVI durability: A rose by any other name is still a rose
Wednesday, 20 Jul 2016
The data that Dvir presented at EuroPCR, as reported by Cardiovascular News, indicate that there is a significant increase in valve degeneration between five and seven years after a transcatheter ... TAVI durability: A rose by any other name is still a rose

Exploring the borders of TAVI
Monday, 11 Jul 2016
The NOTION 2 trial, which recently enrolled a 64-year-old female with Society of Thoracic Surgeon (STS) score 1.2% as its first patient, is comparing the use of TAVI with the use of surgical aortic ... Exploring the borders of TAVI

Profiles


James Blankenship
Wednesday, 08 Jun 2016
James Blankenship is the 2015–2016 president of SCAI and has been involved with designing and ... James Blankenship

Alexandra Lansky
Monday, 07 Mar 2016
Alexandra Lansky (Director, Heart and Vascular Clinical Research Program, Yale University School of ... Alexandra Lansky

Cardiac Rhythm News Vascular News Cardiovascular News Interventional News Spinal News NeuroNews
BIBA Medical BIBA MedTech Insights CX Symposium ilegx
Password Reminder

BIBA Medical, 526 Fulham Road, Fulham, London, SW6 5NR.
TEL: +44 (0)20 7736 8788 FAX: +44 (0)20 7736 8283 EMAIL: 
info@bibamedical.com
© BIBA Medical Ltd is a company registered in England and Wales with company number 2944429.
VAT registration number 730 6811 50.
Site Map | Terms and Conditions